Is a new fast-acting pill for depression the Holy Grail that patients have been waiting for? : vimarsana.com

The FDA approval for the twice-daily pill comes just three months after the publication of positive results of a clinical trial, where it was compared against a placebo.

Related Keywords

United Kingdom , Australia , Massachusetts , United States , Ireland , Cambridge , Cambridgeshire , Canada , University College , New South Wales , London , City Of , Andrew Miller , Mark Horowitz , David Healy , Louise Atkinson , Ted Dinan , Edward Bullimore , Felice Jacka , Carmine Pariante , King College London , University College London , Mcmaster University , Emory University School Of Medicine , Harvard Medical School , United Kingdom Health Security Agency , Good Health , University Of Cambridge , University Of Cork , Mood Centre At Deakin University , Public Health England , European Medicines Agency , Food Drug Administration , Office For National Statistics , Drug Administration , Axsome Therapeutics , Clinical Psychiatry , Maurizio Fava , Massachusetts General Hospital , Benylin Dry Cough , Robitus Sin Dry Cough , Professor Fava , National Statistics , Holy Grail , Breakthrough Therapy , Emory University School , College London , Professor Healy , Daily Mail , Professor Felice Jacka , Mood Centre , Deakin University , Professor Jacka , Nature Translational Psychiatry , Professor Dinan , Dailymail , Health , Fda , Depression ,